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Abstract: Human stem cells from adult sources have been shown to contribute to the regeneration of muscle,
liver, heart, and vasculature. The mechanisms by which this is accomplished are, however, still not well understood.
We tested the engraftment and regenerative potential of human umbilical cord blood-derived ALDH
hiLin
-, and
ALDH
loLin
- cells following transplantation to NOD/SCID or NOD/SCID b2m null mice with experimentally induced
acute myocardial infarction. We used combined nanoparticle labeling and whole organ fluorescent imaging to
detect human cells in multiple organs 48 hours post transplantation. Engraftment and regenerative effects of cell
treatment were assessed four weeks post transplantation. We found that ALDH
hiLin
- stem cells specifically located
to the site of injury 48 hours post transplantation and engrafted the infarcted heart at higher frequencies than
ALDH
loLin
- committed progenitor cells four weeks post transplantation. We found no donor derived
cardiomyocytes and few endothelial cells of donor origin. Cell treatment was not associated with any detectable
functional improvement at the four week endpoint. There was, however, a significant increase in vascular density
in the central infarct zone of ALDH
hiLin
- cell-treated mice, as compared to PBS and ALDH
loLin
- cell-treated mice.
Conclusions: Our data indicate that adult human stem cells do not become a significant part of the regenerating
tissue, but rapidly home to and persist only temporarily at the site of hypoxic injury to exert trophic effects on
tissue repair thereby enhancing vascular recovery.
Introduction
Acute myocardial infarction (AMI) and the resulting
complications are a leading cause of morbidity and mor-
tality in the Western world. While conventional treat-
ment strategies for AMI may efficiently alleviate
symptoms and hinder disease progression, recovery of
lost cells and tissue is rarely achievable. Transplantation
of primitive progenitor cells of hematopoietic, mesench-
ymal, and endothelial lineages have, however, been
found to enhance endogenous tissue repair in small ani-
mal disease models and to improve overall function of
the affected tissues in early phase clinical trials [1]. The
exact mechanism of repair is not known but may
involve paracrine signaling by the donor cells or direct
replacement of damaged tissue by donor cells[2].
Stem and progenitor cells derived from hematopoietic
tissue have attracted much attention as a source of
transplantable cells for cell-based regenerative therapy.
Hematopoietic, mesenchymal, and endothelial progeni-
tors have been identified in human bone marrow (BM)
and umbilical cord blood (UCB) [3-5]. All three progeni-
tor populations can be simultaneously isolated from
human BM based on the expression of the cytosolic
enzyme aldehyde dehydrogenase (ALDH) [6], although
the relative contributions of the different sub-popula-
tions and consequently their relative therapeutic contri-
bution may vary between the different cell sources. We
and others have found that lineage depleted (Lin
-) cells
from BM and UCB that express high levels of ALDH
(ALDH
hiLin) have superior long term repopulating
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scid/scid (NOD/SCID) mice whereas lineage depleted
cells that express low levels of ALDH (ALDH
loLin
-)a r e
virtually devoid of long term repopulating potential in
spite of an apparent overlap in expression of the puta-
tive human hematopoietic stem cell marker CD34
between the two populations [7-10]. Furthermore, as
few as 2 × 10
5 ALDH
hiLin
- cells purified from UCB can
engraft multiple tissues in the b-glucuronidase (GUSB)
deficient NOD/SCID/MPSVII mouse model, including
the pancreas, retina, lung, liver, kidney and heart at 10-
12 weeks post transplantation [11].
Xenotransplantation of human hematopoietic stem
cells and progenitor cells to immune deficient mice is
extensively used to study human hematopoiesis and
diseases involving the hematopoietic system [12]. The
studies of diseases of solid organs using xenotransplan-
tation models is, however, hampered by the lack of sim-
ple and sensitive methods for identifying human donor
cells, an issue which we addressed in the current studies.
We adapted the left anterior descending (LAD) coronary
artery occlusion model of AMI recently described by
van Laake et al [13] to highly immune deficient NOD/
SCID and NOD/SCID b2-microglobulin null mice
(NOD/SCID b2m null). The NOD/SCID b2m null
mouse strain is deficient in the expression of the MHC
class I associated cell surface protein b2-microglubulin
(b2m), which is normally expressed on all nucleated
cells [14]. Engrafting donor cells can thus easily be
detected by immune staining for b2m.
Macroscopic evaluation of donor cell distribution to
various organs following global or localized delivery is
key to understanding the dynamics of stem cell engraft-
ment in target tissues and has been described using
labeling with radionuclides, fluorescent dyes, or biolumi-
nescent or fluorescent reporter proteins [15,16]. We
have recently documented that engrafting human donor
cells can be visualized in situ without adversely affecting
cell viability and engraftment potential by a combination
of nanoparticle labeling and whole organ fluorescent
imaging [17]. Using a similar approach, we have in the
present study: 1) evaluated donor cell distribution to
multiple organs, including the infarcted heart, at 48-72
hours post transplantation and 2) analyzed long term
engraftment in multiple organs and the infarct zone as
well as the regenerative effects of cell treatment by
molecular and mechanistic approaches at four weeks
post transplantation. By the combined nanoparticle
labeling and whole organ fluorescent imaging, we found
a more pronounced infarct-specific distribution of
ALDH
hiLin
- stem cells, as compared to committed pro-
genitor cells at 48-72 hours post transplantation. At
four weeks post transplantation, ALDH
hiLin
- cells
engrafted multiple organs, including the heart, liver and
kidney, at higher frequencies than ALDH
loLin
- cells.
Under these highly permissive conditions for human cell
engraftment, we found no donor derived cardiomyocytes
and only few endothelial cells of donor origin at four
weeks. Cell treatment was not associated with a signifi-
cant improvement in cardiac performance at four weeks.
There was, however, a significant increase in the vascu-
lar density of large caliber vessels in the central infarct
zone of ALDH
hiLin
- cell-treated mice, as compared to
PBS and ALDH
loLin
- cell-treated animals.
Materials and methods
Mice
NOD/SCID and NOD/SCID b2m null mice (originally
from Jackson Laboratories, Bar Harbor, ME) were bred
and maintained at the animal facilities at the Washing-
ton University School of Medicine. All animal experi-
ments and protocols were approved by the animal
studies committee at Washington University School of
Medicine, and conducted in compliance with the Guide
for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publica-
tion No. 85-23, revised 1996), and all University
requirements.
Human cell purification
Umbilical Cord Blood (UCB) that failed to meet the
minimal total nucleated cell count was obtained from
the cord blood banking facility at Cardinal Glennon
Children’s Hospital, St Louis, MO, and used in accor-
dance with the ethical guidelines at Washington Univer-
sity School of Medicine and the principles outlined in
the Declaration of Helsinki. Mononuclear cells (MNCs)
were isolated from UCB by Hypaque-Ficoll centrifuga-
tion (Pharmacia Biotech, Uppsala, Sweden). MNCs from
different cord blood samples were pooled (24 cords
were used in total) and lineage depleted or enriched for
CD34
+ cells as previously described [8]. Briefly, UCB
MNCs were incubated with a human-specific lineage
depletion antibody cocktail or anti human CD34 anti-
body followed by magnetic bead labeling before negative
or positive selection, respectively, on an immunomag-
netic separation column, according to the manufac-
turer’s directions (Stem Cell Technologies, Vancouver,
BC, Canada).
FACS sorting of aldehyde dehydrogenase high and low
expressing cells
Cells to be sorted were cultured overnight in X-Vivo 15
media (Lonza Group, Basel, Switzerland) on RetroNectin
coated plates (25 μg/cm
2; Takara Bio INC., Otsu, Japan)
in the presence of recombinant human SCF, Flt3-L and
TPO (all 10 ng/ml, R&D Systems, Minneapolis, MN)
and nano-particles in selected experiments as indicated
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gentle washing with Cell Dissociation Buffer (CDB, Invi-
trogen, Carlsbad, CA) and purified according to their
levels of ALDH activity by staining with the Aldefluor
reagent (Aldagen, Durham, NC), according to the manu-
facturer’s specifications. Briefly, Aldefluor substrate
(0.625 μg/mL) was added to 1 to 5 × 10
6 Lin
- cells/mL
suspended in Aldefluor assay buffer and incubated for
20 to 30 minutes at 37°C. Cells were then FACS sorted
on a MoFlo (BD, San Jose, CA) according to high and
low Aldefluor signal as described [8].
Whole organ fluorescent imaging
655 nm fluorescent emitting nano-particle labeling
Human UCB Lin
- or CD34
+ cells were incubated with
655 nm fluorescent Quantum Dot nano crystals
(QD655, Invitrogen) in cell media (X-Vivo with recom-
binant human SCF, Flt3-L and TPO (all 10 ng/ml)) in
t h ep r e s e n c eo f0 . 1n Mp r o t a m i n es u l p h a t ef o r1 5m i n
followed by overnight incubation in cell media at 10
6
cells/well on Retronectin coated non-tissue culture trea-
ted 24 well plates at 37°C and 5% CO2. The following
day the Lin
- cells were then detached by gentle washing
with CDB and resuspended in PBS and sorted according
to high or low expression of ALDH as described above.
The cells were then subjected to a second round of
labeling overnight as described. CD34+ sorted cells were
labeled in parallel but without sorting for ALDH
activity.
750 nm fluorescent emitting nano-particle labeling
The 750 nm fluorescently labeled paramagnetic Feridex
iron nanoparticle protocol was essentially identical to
the 655 nm nano-particle labeling protocol with the fol-
lowing modifications: Human UCB Lin
- cells were only
subjected to a single round of labeling followed by sort-
ing for high and low expression of ALDH as described.
Labeled and sorted cells were incubated overnight in
cell media without further labeling.
Transplantation of nano-labeled cells
Cells to be transplanted were detached on the following
day by gentle washing with CDB and maintained in cell
media until transplantation. NOD/SCID or NOD/SCID
b2m null mice to be transplanted were subjected to
AMI on the day before transplantation as described [18]
and transplanted with QD655 or Feridex750 labeled
cells (2 × 10
6 CD34
+,1 . 6-4×1 0
5 ALDH
loLin
-;2 . 3-
4×1 0
5 ALDH
hiLin
-)b yas i n g l ei n t r a v e n o u s( I V )i n j e c -
tion via the tail vein. PBS injected or control animals
(no AMI) were analyzed in parallel. Mice were sacrificed
48 - 72 hours post transplantation and organs were har-
v e s t e d ,r i n s e di nP B Sa n da n a l y z e do naK o d a k4 0 0 0
MM CCD/X-ray imaging station (Molecular Imaging
Systems, Eastman Kodak Company, New Haven, CT) as
described [17]. Relative intensities were measured by
comparing regions of interest (ROI) applied to the tissue
images. ROI values of untreated controls were defined
as 1.
Four week transplantation experiment
NOD/SCID b2m null mice to be transplanted were sub-
jected to AMI on the day before transplantation, as
described [18]. Human UCB Lin
- cells were sorted
according to high or low expression of ALDH as
described above and 0.5-1 × 10
6 ALDH
loLin
- (n = 6) or
0.6-1 × 10
6 ALDH
hiLin
- (n = 11) cells or PBS (n = 13)
was transplanted by a single IV injection. Mice were
sacrificed 28 days post transplantation and organs were
harvested and processed for frozen sectioning.
Echocardiography
Transthoracic echocardiography was performed in
anesthetized mice by using an Acuson Sequoia 256
Echocardiography System (Acuson Corp., Mountain
View, California, USA) equipped with a 15-MHz (15L8)
transducer as previously described [19]. Ejection fraction
(EF), left ventricular end diastolic volume (LV-EDV), left
ventricular end systolic volume (LV-ESV), and segmen-
t a lw a l lm o t i o ns c o r i n gi n d e x( S W M S I )w e r ee v a l u a t e d
on the day of transplantation (day 1 post surgery) and at
one and four weeks post transplantation as described
[20]. Animals were stratified into groups with small,
medium and large infarcts, as described [20]. The echo-
cardiographer was always blinded to the specific treat-
ments of the animals.
Immunofluorescence
Hearts, spleens, lungs, livers, and kidneys were quickly
removed and placed in PBS at room temperature for
5 minutes to allow excess blood to drain out. The
organs were then placed in ice-cold PBS and processed
for frozen sectioning. Hearts were cut into three trans-
verse sections in a bread loaf manner and embedded in
O.C.T compound before rapid freezing in liquid nitro-
gen cooled acetone/methanol. Spleens and sections from
livers, lungs, and kidneys were processed in parallel.
5 μm frozen sections were mounted on Superfrost
microscope slides. Human cells were detected using
human specific antibodies: rabbit anti-b2-Microglobulin
(1:800, Abcam, Cambridge, United Kingdom), mouse
anti-CD45 (1:200, Vector Laboratories, Burlingame, CA)
and mouse anti-CD31 (1:100, DAKO, Glostrup, Den-
mark). Staining was visualized using highly cross-
adsorbed goat anti-mouse or anti-rabbit secondary anti-
bodies conjugated with either Alexa488 or Alexa594
antibodies (1:000, all Invitrogen) and sections were
mounted with DAPI containing Neomount mounting
medium (Invitrogen). Relevant isotype controls were
stained in parallel. Comparable frozen sections of hearts
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negative and positive controls, respectively. Sections
were analyzed on a Zeiss Axiovert4000 wide field fluor-
escent microscope (Carl Zeiss Inc., Oberkochen, Ger-
many) using the Metamorph software (Molecular
Devices, Sunnyvale, CA). Image stacks of thin serial sec-
tions were obtained from selected sections by Z-stage
scanning. Blinded 3D deconvolution (Autoquant, Media
Cybernetics, Inc., MD) was used to reduce out of focus
light and enhance signal to noise ratio. Single thin opti-
cal sections were generated using the ImageJ software
( R a s b a n d ,W . S . ,I m a g e J ,U .S .N a t i o n a lI n s t i t u t e so f
Health, Bethesda, Maryland, USA, http://rsb.info.nih.
gov/ij/, 1997-2006).
Vascular density
5 μm frozen sections from the basal and medial portion
of the hearts from each treatment group (PBS: n = 12;
ALDH
loLin
-:n=5 ;A L D H
hiLin
-:n=9 )w e r es t a i n e d
with mouse-specific rat anti-CD31 antibody (1:100, BD
Biosciences, San Diego, CA) and visualized using a
HRP-conjugated secondary goat anti-mouse antibody
(Acriz Antibodies GmbH, Hiddenhausen, Germany) and
DAB+ chromagen according to the manufacturer’s
instruction (DAKO). For each heart, bright field images
were recorded from 10 randomly selected visual fields
(40× magnification) in the tissue sub-served by the
infarct related artery. Mean vascular density per μm
2 tis-
sue was estimated for each group. Only CD31 positive
structures with a well defined tubular morphology or
structures with a linear extension equal to or larger
than 50 μm were scored as positive. Images were ana-
lyzed using the ImageJ software.
Statistical analyses
All data were analyzed by ANOVA with Bonferroni cor-
rection for multiple comparisons. p-values smaller than
or equal to 0.05 were considered significant. Hadis
method to identify outliers in multivariate data [21] was
applied to the vascular density data with a 95% signifi-
cance level.
Results
Distribution of ALDH
loLin
-, ALDH
hiLin
-, and CD34
+ cells at
48-72 hours post transplantation
We first evaluated the short term homing potential of
three human stem and progenitor cell populations,
ALDH
hiLin
-,A L D H
loLin
-,a n dC D 3 4
+, purified from
UCB as previously described [8]. Purified cells were
labeled with QD655 or Feridex750 fluorescent particles
(2 × 10
6 CD34
+, 1.6 - 4 × 10
5 ALDH
loLin
-; 2.3 - 4 × 10
5
ALDH
hiLin
-), transplanted to NOD/SCID or NOD/SCID
b2m null mice with surgically induced AMI and selected
organs were analyzed on a Kodak 4000 MM CCD/X-ray
imaging station 48-72 hours post transplantation as
described [17] (Figure 1). We found greater signal inten-
sity at the site of injury in the hearts of ALDH
hiLin
- cell
treated animals, as compared to ALDH
loLin
- cell treated
mice (Figure 1A). Donor cells were predominantly
l o c a t e da tt h es i t eo fi n j u r ya se v i d e n tf r o mi m a g e s
taken of the posterior, non-infarcted wall (Figure 1B).
Although based on limited data, it was also interesting
to note that CD34
+ cells, although representing a major
sub-population in the ALDH
hiLin
- fraction, did not
appear to home with the same specificity or robustness.
To exclude the possibility that the fluorescent signal was
derived from contaminating free nanoparticles co-
injected with the donor cells, we sorted for high or low
ALDH expression after labeling with Feridex750 nano-
particles and prior to transplantation. As can be seen in
Additional file 1, we confirmed the preferential infarct
specific distribution of the ALDH
hiLin
- sorted cells.
Interestingly, using cells purified after Feridex nanoparti-
cle labeling, it could be observed that ALDH
loLin
- cells,
which represent a committed progenitor population,
appeared to traffic to the spleen at greater frequency in
comparison to ALDH
hiLin
- cells, as evident from the
higher fluorescent intensity in the spleens of animals
transplanted with ALDH
loLin
- cells, as compared to ani-
mals that received ALDH
hiLin
- cells. In contrast, as also
seen in figure 1, the more primitive ALDH
hiLin
- stem cell
population preferentially homed to the infarcted heart.
Multi-organ engraftment
Next, we evaluated the engraftment and regenerative
potential of highly purified ALDH
loLin
- and ALDH
hiLin
-
cells that had been FACS sorted from human Lin
- UCB
in NOD/SCID b2m null mice with surgically induced
AMI four weeks post transplant (ALDH
loLin
- (n = 6) or
ALDH
hiLin
- (n = 11) cells or PBS (n = 13)).
The NOD/SCID b2m null mouse strain is null for the
MHC-I associated b-2-microglobulin gene product that
is expressed on all nucleated cells. This allowed us to
specifically detect human cells regardless of phenotypic
fate in the murine background by antibody-mediated
staining for b2m. Sections from spleen, lung, kidney,
liver and heart revealed human engraftment in 10 of 11
ALDH
hiLin
-transplanted animals (Figure 2) and in four
of six ALDH
loLin
- transplanted animals (data not
shown). The human engraftment in the ALDH
hiLin
-
transplanted animals was generally more widespread
with human cell present in the spleen, lung, liver, heart,
and kidney. Only sporadic human cells were detected in
ALDH
loLin
- transplanted animals and never in multiple
organs of the same animal (data not shown). Engrafting
human cells appeared small and round to oval shaped
with a small cytoplasm relative to the nucleus. Engraft-
ment appeared evenly dispersed throughout the tissues,
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+,A L D H
loLin
-,o rA L D H
hiLin
- sorted cells to the site of injury in NOD/SCID mice with AMI.
AMI was induced in NOD/SCID mice by permanent ligation of the LAD. On the following day, animals were transplanted with 2 × 10
6 CD34
+,4×
10
5 ALDH
loLin
-,o r4×1 0
5 ALDH
hiLin
- UCB cells labeled with QD655 fluorescent nanoparticles. Hearts were removed 48 hours post transplant and
near infra-red images were recorded. (A) Anterior wall, (B) posterior wall. Values indicate relative fluorescent intensity. Value of the control is set at 1.
Figure 2 Multi-organ engraftment in NOD/SCID b2m null mice four weeks after transplantation of ALDH
hiLin
- sorted human UCB cells.
NOD/SCID b2m null mice with AMI were transplanted with ALDH
hiLin
- sorted human UCB cells and human engraftment in multiple organs was
assessed by staining for human specific b2m four weeks post transplant. (A) Spleen, (B) lung, (C) liver, (D) kidney, (E) heart, (F) liver. Nuclei: blue,
b2m: red. Scale bar represents 25 μm.
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or more cells (Figure 2F).
Engrafting human cells were further characterized by
double staining for human-specific b2m in combination
with either a human-specific CD45 pan-leukocyte anti-
body or a human-specific CD31 endothelial antibody.
CD45 positive cells accounted for the majority of the
engrafting cells (Figures 3A-L). We found very few
donor derived CD31 positive cells (representative stain-
ing from the lung shown in Figures 3M-P).
Cardiac engraftment
We analyzed hearts from the two cell-treated groups in
greater detail. To estimate the level of engraftment, we
identified b2m-positive nucleated human cells in a total
of 150 individual sections obtained from the basal, med-
ial, and apical portions of the hearts. Human engraftment
in the heart, defined as the presence of at least three indi-
vidual b2m- positive cells in the combined tissue ana-
lyzed from the basal, medial, or apical sections, was seen
in 10 of 11 ALDH
hiLin
- transplanted animals. Human
cardiac engraftment was determined by PCR on purified
DNA from thin frozen sections as described [22] and
revealed that all of the ALDH
hiLin
- treated animals but
none of the ALDH
loLin
- treated animals were positive for
human specific Alu sequence. We have recently reported
this same phenomenon in the liver, with only the
ALDH
hi cells homing to the site of tissue damage, as ver-
ified by FACS and ALU analysis [23]. Human cells were
found in only one of the ALDH
loLin
- transplanted ani-
mals. For each section analyzed, we found 1 to 10 human
cells in the hearts of ALDH
hiLin
- cell-transplanted ani-
mals. The human cells were primarily found as individual
cells located in the non-infarcted healthy myocardium
Figure 3 Multi-lineage human engraftment in selected organs in NOD/SCID b2m null mice four weeks after transplantation of ALDH
hi
Lin
- sorted human UCB cells. NOD/SCID b2m null mice with AMI were transplanted with ALDH
hiLin
- sorted human UCB cells. The lineage of
human engrafting cells in selected organs was assessed by double staining for human-specific b2m and CD45 (A-L) or CD31 (M-P) four weeks
post transplantation. (A-D) Lung, (E-H) Kidney, (I-L) Spleen, (M-P) Lung. Nuclei: blue, CD45 and CD31: green, b2m: red. Scale bar represents
25 μm.
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border. Occasionally two or three cells were found clus-
tered together. The human cells were small and round to
oval shaped with a small cytoplasm relative to the
nucleus. We found no cells with cardiomyocyte morphol-
ogy in the 150 individual sections analyzed. Staining for
human hematopoietic and endothelial cells with human-
specific CD45 or CD31 antibodies, respectively, revealed
a pattern similar to that found in the lung, liver, kidney,
and spleen. The majority of the human cells co-expressed
CD45 (Figure 4D) while b2m/CD31 double positive
human cells were rare and not integrated in the epithe-
lium of large caliber vessels (Figure 4H).
Functional recovery
We have previously shown that the initial infarct size in
the murine AMI model is critical for the disease pro-
gression and late infarct size [20]. Thus, animals that
only receive a small infarct recover easily from injury to
levels comparable to sham operated controls. Stratifying
the mice based on the day 0 infarct size in the present
study did not, however, influence the interpretation of
the data and all transplanted animals were included in
the final evaluation.
NOD/SCID b2m null mice with AMI were trans-
planted with ALDH
loLin
- (Figure 5 - Red square) or
ALDH
hiLin
- (Figure 5 - Green triangle) sorted human
UCB cells or PBS (Figure 5 - Blue diamond). Serial
echocardiographic images were recorded for all treat-
ment groups (PBS, ALDH
loLin
-,a n dA L D H
hiLin
-)o n
the day following surgery (day 0) and again at one and
four weeks post transplantation. All treatment groups
had similar sized infarcts at the time of transplantation,
as evident from day 0 SWMSI. There was no improved
cardiac function at the experimental end point. At four
weeks, we thus found no significant difference in EF,
LV-EDV, LV-ESV or SWMSI between any of the treat-
ment groups (Figure 5).
Vascular density
We analyzed whether the transplanted cells promoted
re-vascularization of the infarcted tissue by host
endothelial cells. Sections were stained with a murine-
specific CD31 endothelial antibody and we evaluated the
mean vascular density in the infarcted tissue sub-served
by the infarct related artery normalized to the μm
2 tis-
sue analyzed. CD31 is expressed on platelets and a num-
ber of hematopoietic cell types that infiltrate infarcted
tissue including macrophages, neutrophils, and NK cells
[24]. To avoid the potential inclusion of non-endothelial
cell types (Figure 6, open arrows) in the estimation of
vascular density, we only counted CD31 positive struc-
tures with a well defined tubular morphology or an
open lumen, or structures with a linear extension equal
to or larger than 50 μm (Figure 6, solid arrows). We
found a mean capillary density of 6.0, 5.4, and 4.1 large
caliber vessels pr. 1000 μm
2 tissue in the ALDH
hiLin
-,
ALDH
loLin
- and PBS treated groups, respectively (95%
confidence interval [5.0-7.0], [4.4-6.5], [3.3-5.0]; Table
1). We found a significant increase in capillary density
in the ALDH
hiLin
- treated group as compared to the
PBS treated group at four weeks post transplantation
(p = 0.011 versus PBS; Table 1). Although the ALDH
lo-
Lin
- treated group was not significantly different from
the PBS treated group, we noted a tendency toward an
intermediate improvement in vascular density in the
Figure 4 Human engraftment in the heart of NOD/SCID b2m null mice with AMI four weeks after transplantation of ALDH
hi Lin
-
sorted human UCB cells. NOD/SCID b2m null mice with AMI were transplanted with ALDH
hiLin
- sorted human UCB cells. The lineage of
human engrafting cells in selected organs was assessed by double staining for human specific b2m and CD45 (A-D) or CD31 (E-H) four weeks
post transplantation. Nuclei: blue, CD45 and CD31: green, b2m: red. Scale bar represents 25 μm.
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loLin
- treated groups. Using the Hadis method to
identify outliers in multivariate data [21] with a 95% sig-
nificance level eliminated two high power fields in the
PBS treated groups and one outlier in the ALDH
hiLin
-
treated group. Between group comparison after elimina-
tion of outliers revealed that both the ALDH
hiLin
- trea-
ted and the ALDH
loLin
- treated groups were
significantly different from the PBS treated group (p =
0.001 and p = 0.031, respectively).
Discussion
In the current studies we have adapted the LAD occlu-
sion model of AMI to immune deficient NOD/SCID and
NOD/SCID b2m null mice. We used this model to evalu-
ate the global engraftment potential of purified human
UCB cell populations as well as the distribution, engraft-
ment, and regenerative potential for the infarcted heart.
We first used fluorescent nanoparticle labeling to trace
the donor cell distribution to various organs, including
the infarcted myocardium, following IV injection. We
have recently documented that sorting of the labeled
cells is essential to avoid infusing large numbers of
unbound nanoparticles [17]. Non-cell mediated splenic
sequestering of fluorescent nanoparticles was indeed
pronounced in our previous report when control NOD/
SCID b2m null mice received free 750 nm fluorescently
conjugated Feridex nanoparticles [17]. The fluorescent
intensities found in the NOD/SCID mice transplanted
with QD655 labeled cells in the present study may thus
include both cell specific and unspecific non-cell
mediated fluorescence. Our present results from animals
transplanted with 750 nm Feridex labeled cells sorted
prior to infusion, however, confirm a significant distri-
bution of labeled donor cells to the infarcted tissue in
the absence of nonspecific signal from free nanoparti-
cles. We have previously found a labeling efficiency
between 28% and 40% with fluorescently conjugated
Feridex nanoparticles, depending of the purification
Figure 5 Cardiac function of NOD/SCID b2m null mice with AMI four weeks after transplantation of ALDH
lo Lin
- or ALDH
hi Lin
- sorted
human UCB cells or PBS. NOD/SCID b2m null mice with AMI were transplanted with ALDH
loLin
- (Red square) or ALDH
hiLin
- (Green triangle)
sorted human UCB cells or PBS (Blue diamond). Echocardiographic images were recorded on the day of transplantation (day 0) and again at day
7 and day 28. Segmental wall motion scoring index (A), end diastolic volume (B), end systolic volume (C), and ejection fraction (D) were
determined. Data points indicate mean values and standard error.
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Page 8 of 13method [17]. Specifically, the Feridex labeling efficiency
of UCB CD34
+ purified cells was approximately 32%
while Lin
- purified UCB cell labeled at approximately
39%. Although we did not measured the QD655 and
Feridex nanoparticle labeling efficiency of the Lin
-
ALDH
hi and Lin
-ALDH
lo purified cells used in the pre-
sent study, we expect that differential labeling efficiency
is not responsible for the observed difference in signal
intensity. Although we were clearly able to visualize a
specific trafficking of ALDH
hiLin
- cell to the site of
i n j u r y ,w ew e r eu n a b l et oi m a g et h eo r g a n sn o n - i n v a -
sively thus precluding a longitudinal evaluation of donor
cell distribution. Using a similar cell sorting and labeling
strategy we, however, recently demonstrated that donor
cells could be detected in the ischemic hind limb up to
seven days after transplantation [17]. The difference in
sensitivity between our previous study and the present
one is likely due to interference from the additional
overlying tissue of the thoracic cavity and localized
transplantation and/or labeling with fluorescent nano-
particles emitting in the far red range may be needed in
order to improve tissue penetration and allow non-inva-
sive visualization of labeled cells in situ [17]. Also, the
electron-dense properties of the fluorescent nanoparti-
cles presently employed potentially allow for multimodal
non-invasive visualization of labeled cells using both
fluorescent and magnetic resonance imaging [17]. We
have also recently worked with perfluorocarbon nano-
beacons, which have a higher emission and penetrance
without background and might be better suited for in
vivo imaging of deep tissues [17].
Both the NOD/SCID and the NOD/SCID b2m null
strains presently used are known to support multi-line-
age engraftment of human hematopoietic cells. Identifi-
cation of engrafting human cells in solid organs is,
however, difficult and requires labeling of donor cells
prior to transplantation by ex vivo manipulation of tar-
get cells prior to transplantation or by application of
complex immunoassay techniques. Extensive ex vivo
manipulation of the donor cells is undesirable and may
adversely affect the cells and increase the risk of con-
tamination while antibody staining for specific human
lineage markers typically requires knowledge of the
expected differentiation pattern of the transplanted cells,
so unexpected cell phenotypes may go unnoticed. Anti-
body staining for b2m is, on the other hand, quick and
versatile, and requires no ex vivo manipulation of the
donor cell. Moreover, no nonspecific staining of endo-
genous b2m is seen in NOD/SCID b2m null strain and
donor derived cells are detected regardless of post trans-
plantation phenotypic fate. A drawback of the b2m
staining approach relates to the possible down regula-
tion of b2m expression by some types of cancer cells as
a mechanism to avoid normal host cancer surveillance
[25]. Although we are not aware of any literature
describing a similar down regulation of b2m expression
by non-carcinogenic cells in the setting of xenogeneic
transplantation, we cannot exclude the fact that we may
underestimate the number of engrafting human cells by
this method. To compensate for this shortcoming and
to confirm the human specificity of our b2m staining,
we employed human specific lineage specific antibodies
Figure 6 Vascular density in the infarct zone of NOD/SCID b2m
null mice with AMI four weeks after transplantation of ALDH
lo
Lin
- or ALDH
hi Lin
- sorted human UCB cells. NOD/SCID b2m null
mice with AMI were transplanted with ALDH
loLin
- or ALDH
hiLin
-
sorted human UCB cells or PBS. Frozen sections were stained with a
mouse specific CD31 antibody and visualized with DAB+
chromagen. Ten high power fields were recorded from each heart
(PBS: n = 12; ALDH
loLin
-: n = 5; ALDH
hiLin
-: n = 9) in the tissue sub
served by the infarct related injury. Representative CD31 labeling
from the infarct zone of an ALDH
hiLin
- or ALDH
loLin
- transplanted
animal are shown in (A) and (B), respectively. Arrows point to
representative CD31 stained structures that were excluded (open
arrows) or included (solid arrows) in the estimation of vascular
density. See text for further explanation. Nuclei: blue, CD31: brown.
Scale bar represents 50 μm.
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Page 9 of 13throughout the study. Alternatively, we have also
recently described an alternative murine xenograft
model based on the b-glucuronidase (GUSB) deficient
NOD/SCID/MPSVII mouse strain [17,23]. The lack of
GUSB expression by the host tissue similarly allows
rapid and precise identification of engrafting human
cells by staining for donor GUSB activity. Using the
NOD/SCID/MPSVII model, wed e m o n s t r a t e dm u l t i -
organ engraftment of human UCB-derived ALDH
hiLin
-
cells 10-12 weeks post transplantation [11]. Both the
present model and the NOD/SCID/MPSVII model are
thus ideally suited for pre-clinical evaluation of prospec-
tive cell populations and application strategies in cell-
based regenerative therapy.
We and others have previously shown that ALDH
hi-
Lin
- cells have a superior hematopoietic repopulating
potential in the BM and spleen of NOD/SCID and
NOD/SCID b2m null mice, as compared to CD34
+ or
ALDH
loLin
- cells [7-10]. ALDH
loLin
- cells are, as veri-
fied in the present study, indeed virtually devoid of long
term repopulation potential. In addition, we have
recently shown that ALDH
hiLin
- sorted cells from
human BM contained populations of functionally primi-
tive mesenchymal progenitor populations [26]. UCB, as
used in the present study, is, however, known to contain
lower numbers of mesenchymal progenitors in compari-
son to BM [17]. We cultured the cells overnight under
conditions that promote retention of primitive hemato-
poietic phenotypes [17]. The present AMI xenotrans-
plantation study thus predominantly reflects the
regenerative potential of highly purified hematopoietic
stem and progenitor cells. Gentry et al. have previously
shown that ALDH
hi sorted cells contain subsets of pri-
mitive stem and progenitor cells of non-hematopoietic
lineages, including mesenchymal stem cells and
endothelial progenitor cells [6]. Although we did not
assess the proportion of these non-hematopoietic cells
in the present study, due to the cell source and isolation
a n dc u l t u r em e t h o d ,i ti su n l i k e l yt h a tt h e yc o n t r i b u t e d
to the observed results in a substantial way. We found
no evidence of a direct contribution of the transplanted
cells to regenerated infarcted tissue although down reg-
ulation of b2m expression by the donor cells as dis-
cussed above may have rendered some donor-derived
cells types undetectable by our present methods.
Engrafting human cells were predominantly of a hema-
topoietic phenotype, although non-hematopoietic cells
were also identified. These CD45 negative cells rarely
appeared in the infarcted tissue and it is therefore unli-
kely that they represent primitive cardiomyocytes. We
were unable to precisely determine if the engrafting
cells were tissue resident cells or circulating hemato-
poietic cells retained in the microvasculature. Although
none of the donor cells appeared to reside in large cali-
ber vessels we did, however not analyze peripheral
blood samples to confirm the presence of a circulating
pool of donor derived cells. Moreover, although we
recently reported that fusion of human donor UCB
ALDH
hiLin
- cells and host murine hepatocytes could
generate hybrid cells that only retained minimal
amounts of human DNA in a NOD/SCID/MPSVII liver
injury model, this was indeed a very rare event [23].
The present results are thus more in line with our pre-
vious results and recent reports on the role of donor
hematopoietic cells in the regeneration of damaged tis-
sue [17,26-28]. In a recent study we also failed to
detect any long term human myocardial engraftment
or functional improvement following intramyocardial
injection of human CD34
+ sorted mobilized peripheral
blood progenitors in athymic nude rats with AMI [29].
In the present study we were similarly unable to detect
an improvement in cardiac function as a result of cell
treatment in either the ALDH
loLin
- or ALDH
hiLin
-
treated groups. We did, however detect a significantly
better vascularization of the central infarct area in the
ALDH
hiLin
- treated group as compared to the ALDH
lo-
Lin
- and PBS treated groups. The fact that the ALDH
lo-
Lin
- cells also appeared to improve vascular density
compared to PBS when correcting for outliers sug-
gested that this population, although devoid of long
term repopulating cells, may include a transiently pre-
sent population of cells with angiogenic potential.
Table 1 Mean vascular density in the infarct zone of NOD/SCID b2m null mice with AMI four weeks post transplant of
PBS, ALDH
lo Lin
- or ALDH
hi Lin
- sorted human UCB cells
Treatment
a n
b Mean vascular density/1000 μm
c 95% Confidence interval p versus PBS
PBS 12 4.1 [3.3-5.0] -
ALDH
loLin
- 5 5.4 [4.4-6.5] 0.279 (0.031)
d
ALDH
hiLin
- 9 6.0 [5.0-7.0] 0.011 (0.001)
d
a NOD/SCID b2m null mice with AMI were transplanted with ALDH
loLin
- or ALDH
hiLin
- sorted human UCB cells or PBS. Frozen sections were stained with a mouse
specific CD31 antibody and visualized with DAB+ chromagen.
b Number of hearts analyzed pr. group; 10 randomly selected visual fields (40× magnification) in the tissue sub-served by the infarct related artery were analyzed
from each heart.
c CD31 positive vascular structures with a well defined tubular morphology or an open lumen or structures with a linear extension equal to or larger than 50 μm
were included.
d p-value after correction for outliers.
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study of cell-based regenerative therapy for AMI reports
a modest 2.5% increase in left ventricular EF following
intra-coronary infusion of BM MNCs [30]. We were
unable to detect an improvement in cardiac function as
a result of cell treatment in either the ALDH
loLin
- or
ALDH
hiLin
- treated groups. It should, however, be
noted that the study was not powered to detect small
improvements in cardiac function and modest improve-
ments as reported in clinical trials would thus go unno-
ticed in the present study. The fact that we found a
superior vascularization in the ALDH
hiLin
- treated
group but no improvement in cardiac function may
indeed be due to the relatively large variation in the
echocardiographic data. The lack of a detectable func-
tional improvement can, alternatively, be explained by
the early end point of functional evaluation. It is indeed
at this point not clear whether the vascular structures
that we detected in the central infarct area are patent
and thus represent mature and functional blood vessels.
T h e s eq u e s t i o n sm a yb er e s o l v e di nf u t u r es t u d i e sb y
both including a more direct measure of blood flow to
the infracted area as well as extending the evaluation
period to eight weeks and beyond. Nonetheless, a long
term benefit is not likely to depend on a direct contri-
bution of the transplanted cells to the regenerating myo-
c a r d i u m ,s i n c ew ef o u n dn oe v i d e n c eo fas u b s t a n t i a l
donor derived population in the central infarct area or
in the blood vessels. These results are in agreement with
our recent findings that human BM derived ALDH
hiLin
-
cells improve perfusion to the ischemic hind limb of
NOD/SCID b2m null mice and improve vascular density
as compared to ALDH
loLin
- or MNC control treated
mice [26]. Moreover, using a similar labeling strategy as
the one employed in the present study, we found that
the human donor cells only transiently engrafted the
ischemic tissue. Only few cells were detected at 21 to 28
days post transplant in animals receiving ALDH
hiLin
-
cells while animals receiving ALDH
loLin
- cells were
devoid of engrafting donor cells at the endpoint.
Although there are obvious differences with respect to
the cell source and the details of the purification proto-
cols employed in our hind limb ischemia study and the
present study, the lack of long term engraftment of the
ALDH
loLin
- cells as shown in the hind limb ischemia
model is corroborated by the present immunofluores-
cent and PCR data. The sensitivity of our PCR assay
may however allow for a non-detected low level of
engraftment to persist although we have previously been
able to detect ~2 human cells per 10.000 murine cells in
a related PCR system [31]. Even though we found similar
results using UCB and BM in the present cardiac infarc-
tion models and in our previously reported hind limb
ischemia model, respectively, in a direct comparison of
BM and UCB derived human CD133
+ purified cells, Ma
et al found that only BM derived cells induced functional
recovery as measured by improved shortening fraction
at four weeks post intramyocardial transplantation of
5×1 0
5 human donor cells in a NOD/SCID cryo-injury
model of AMI [32]. Interestingly, in spite of the signifi-
cant difference in functional recovery between UCB and
BM treated animals, no difference was observed in infarct
size and capillary density between the two cell treatment
groups.
In conclusion, we found that a larger proportion of
human UCB cells selected according to high expression
of the cytosolic enzyme aldehyde dehydrogenase specifi-
cally distributed to the infarcted tissue as compared to
cells with low aldehyde dehydrogenase activity. ALDH
hi-
Lin
- cells also had a superior global engraftment poten-
tial in multiple organs including the infarcted heart at
four weeks post transplantation. Although no significant
improvement in cardiac performance was detected at
four weeks post transplantation, the superior engraft-
ment potential was associated with an increased vessel
density in the infarct zone, as compared to controls.
The significant increase in vessel density in the stem
cell-injected mice, as compared to the injured but non-
transplanted, or committed progenitor - transplanted
controls, is interesting, and the mechanism responsible
is not yet known. The increased density of large-caliber
vessels could be caused by an enlargement in size and
function of pre-existing tiny vessels, or could be caused
by neovascularization into the infarct zone. Future stu-
dies will examine those possibilities.
Additional file 1: Distribution of human UCB ALDH
loLin
-,o r
ALDH
hiLin
- nanoparticle-labeled and re-sorted cells to the site of
cardiac injury vs. spleen in NOD/SCID b2m null mice with AMI. AMI
was induced in NOD/SCID b2m null mice by permanent ligation of the
LAD. On the following day, animals were transplanted with 2 × 10
6 CD34
+,
4×1 0
5 ALDH
loLin
-,o r4×1 0
5 ALDH
hiLin
- UCB cells that had been labeled
with Feridex750 fluorescent nanoparticles and then sorted to remove
unbound particles. Hearts were removed 48 hours post transplant and
near infra-red images were recorded. (A) Anterior wall-infarct site,
(B) spleen lodgment. Values indicate relative fluorescent intensity.
Value of the control is set at 1.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-5876-8-24-
S1.PDF]
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